68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease

• Status: Not yet recruiting
• Trial end date: 2024-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim is to examine the expression of αvβ3 integrin using a novel selective radiotracer in patients with chronich ischemic heart disease and investigate if it is a suitable tool for predicting myocardial recovery and thus prognosis after intervention.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Rigshospitalet, Denmark

Criteria

Inclusion Criteria:

• Age over 50 years

• Patient with known chornic ischemic Heart disease admitted to Rigshospitalet to either PCI og CABG

Exclusion Criteria:

• No prior history of Heart surgery

• Not treated with anti-angiogenic medicine

• Subject with pacemaker, cochlear implant or insulin pump

• Pregnancy

• Lactation

• Severe claustrophobia

• Severe obesity (weight above 140kg)

• Conversion from PCI to CABG

• If a subject is in the fertile age, a pregnancy test will be use prior to injection to the PET_tracer

• If a subject is having a severe allergic reaction to the PET-tracer, the person will be excluded for the rest of the trial

• If the PET-tracer is administered subcutaneous, the person will be excluded for the rest of the trial¨

• Type I or II diabetes